U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C17H23NO4
Molecular Weight 305.3688
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BUCUMOLOL

SMILES

CC1=CC=C(OCC(O)CNC(C)(C)C)C2=C1C=CC(=O)O2

InChI

InChIKey=CIJVBYRUFLGDHY-UHFFFAOYSA-N
InChI=1S/C17H23NO4/c1-11-5-7-14(16-13(11)6-8-15(20)22-16)21-10-12(19)9-18-17(2,3)4/h5-8,12,18-19H,9-10H2,1-4H3

HIDE SMILES / InChI

Description

Bucumolol is a beta-adrenergic antagonist. It can be used in the treatment of myocardial ischemia and hypertension.

Originator

Sankyo
35

Approval Year

Unknown
149,124

Targets

Primary TargetPharmacologyConditionPotency
Beta-1 adrenergic receptor
163
Antagonist
2,849
Beta-2 adrenergic receptor
209
Antagonist
2,849

Conditions

ConditionModalityTargetsHighest PhaseProduct
Angina pectoris
110
 Primary
Preclinical
Unknown
Hypertension
575
 Primary
Basic research
Unknown
Ventricular arrhythmia
50
 Primary
Basic research
Unknown
Myocardial ischemia
14
 Primary
Basic research
Unknown

PubMed

Patents

JP2002541233A
406
JPH05310603A
2

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Oral
In Vitro Use Guide
Unknown
ACTIVE MOIETY
Structure of BUCUMOLOL
SALT/SOLVATE (PARENT)
Structure of BUCUMOLOL HYDROCHLORIDE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966